Stock events for Senseonics Holdings, Inc. (SENS)
Senseonics announced a one-for-twenty reverse stock split in October 2025 and transferred its listing to the Nasdaq Global Select Market in November 2025. In Q3 2025, the company reported $8.1 million in revenue, a 90% year-over-year increase, driven by a 160% increase in U.S. new patient starts, but also reported a net loss of $19.5 million. In January 2026, the Eversense 365 CGM system received CE Mark approval for commercialization in Europe, followed by the launch of the first Eversense 365 Automated Insulin Delivery (AID) system integration with twiist in the U.S. In Q4 2025, revenue was $14.3 million, a 72% increase year-over-year, and full-year 2025 revenue reached $35.3 million, up 57% year-over-year, with 103% new patient growth in the U.S. and improved gross margins. However, a Q4 2025 net loss of $20.8 million was reported, and management provided a 2026 revenue outlook of $58 million to $62 million, anticipating a majority of revenue in the second half of the year due to seasonality.
Demand Seasonality affecting Senseonics Holdings, Inc.’s stock price
Demand for Senseonics' products exhibits seasonality, with revenue expected to be weighted towards the second half of the year due to the timing of annual reorders for long-term implantable sensors. January is typically the softest month for new patient growth due to patient resets.
Overview of Senseonics Holdings, Inc.’s business
Senseonics Holdings, Inc. is a medical technology company specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes. Their core business centers around the Eversense CGM platform, which includes implantable systems like Eversense, Eversense XL, Eversense E3, and Eversense 365. These systems measure glucose levels through an under-the-skin sensor, a removable smart transmitter, and a mobile app. The Eversense 365 system is the world's first year-long implantable CGM, and the company generates revenue through system sales, focusing on recurring revenue from annual sensor reorders.
SENS’s Geographic footprint
Senseonics Holdings, Inc. serves healthcare providers and patients in the United States and internationally. The company uses a network of distributors and strategic fulfillment partners to reach its global customer base. Senseonics is headquartered in Germantown, Maryland, United States.
SENS Corporate Image Assessment
Senseonics has focused on enhancing its brand reputation through product innovation and strategic commercial shifts. The Eversense 365 system has been a key driver, aiming to improve the lives of people with diabetes. The approval and launch of Eversense 365 in the U.S. in 2024 led to a 56% increase in their global patient base. Senseonics has been transitioning to a fully-integrated commercial organization, taking back control of global sales, marketing, and commercialization. Increased investment in DTC marketing has driven a 300% increase in patient leads year-over-year in Q3 2025. The CE Mark approval for Eversense 365 in Europe and its integration with the twiist Automated Insulin Delivery system further bolster the company's reputation.
Ownership
Senseonics Holdings, Inc. has a diverse ownership structure, including institutional funds, individual insiders, and the general public. As of December 2025, institutional investors held 16.4% of the company's shares. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., and Geode Capital Management, Llc. Key individual insider holders include Timothy T Goodnow (President and CEO), Mukul Jain (Chief Operating Officer), and Frederick T. Sullivan (Chief Financial Officer).
